NCT00311623View on ClinicalTrials.gov

Sirolimus Before Surgery in Treating Patients With Advanced Localized Prostate Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

August 31, 2006

Primary Completion Date

January 31, 2008

Study Completion Date

June 30, 2010

Conditions
Prostate Cancer
Interventions
DRUG

Rapamycin 3mg

Rapamycin 3mg (Wyeth Pharmaceuticals, 1mg tablets) PO once daily on Days 1-14 with the last dose given on the morning before surgery (Day 15).

DRUG

Rapamycin 6mg

Rapamycin 6mg (Wyeth Pharmaceuticals, 2mg tablets) PO once daily on Days 1-14 with the last dose given on the morning before surgery (Day 15).

PROCEDURE

Radical prostatectomy

Radical prostatectomy performed on Day 15

Trial Locations (3)

21231

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore

27710

Duke Comprehensive Cancer Center, Durham

48109-0942

University of Michigan Comprehensive Cancer Center, Ann Arbor

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

OTHER

NCT00311623 - Sirolimus Before Surgery in Treating Patients With Advanced Localized Prostate Cancer | Biotech Hunter | Biotech Hunter